Pharma Mar S A : Resolutions adopted by the General Shareholders Meeting

CNMV

Markets Directorate General

C/ Edison 4

28006 Madrid

Colmenar Viejo (Madrid), April 15, 2021

In accordance with article 227 of the recast Spanish Securities Market Act (texto refundido de la Ley del Mercado de Valores), is hereby reported the following:

OTHER RELEVANT INFORMATION

The Ordinary General Shareholders' Meeting of Pharma Mar, S.A. at its meeting held today, on second call, approved by a sufficient majority of votes all the proposals that the Board of Directors had agreed to submit to its deliberation and decision.

The full text of the resolutions adopted by the Ordinary General Shareholders' Meeting that are submitted, correspond with the proposed resolutions that were communicated to the Commission through Other Relevant Information (registration number 7890) on March 10, 2021. The text of the resolutions adopted and the result of the votes will be published on the Company's website in the next five days.

Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina

28770 Colmenar Viejo (Madrid) Spain www.pharmamar.com

Annual General Shareholders' Meeting

Resolutions adopted by the General

Shareholders Meeting

COLMENAR VIEJO (MADRID), 15 APRIL 2021

RESOLUTION TO AGENDA ITEM 1

Annual Financial Statements, allocation of results and corporate management:

1. To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2020.
2. To review and, as the case may be, approve the separate report on the status of consolidated non- financial information for the fiscal year ended December 31, 2020. This report is referred to in section 7 of article 49 of the Commercial Code, which forms part of the Management Report of the Pharma Mar Group.
3. To review and, as the case may be, approve the proposed application of the Company's results for the year ended December 31, 2020.
4. To review and, as the case may be, approve the corporate management during the fiscal year 2020.

1. To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2020.
   To approve, under the terms set forth in the relevant statutory provisions, the Annual Financial Statements (Balance Sheet, Income Statement, Statement of Changes in Net Equity, Cash Flow Statement and Notes to the Financial Statements) and Management Report of Pharma Mar, S.A. for fiscal year ended December 31, 2020, as well as the Annual Financial Statements (Balance Sheet, Income Statement, Statement of Changes in Net Equity, Cash Flow Statement and Notes to the Financial Statements) and Management Report of its Consolidated Group -except for the non-financial information included in the latter, which is subject to the approval of the General Shareholders' Meeting as a separate point- for the same period.
   It is expressly stated that the aforementioned accounting documents have been audited by PRICEWATERHOUSECOOPERS Auditores S.L., whose report, together with all other documents forming part of the Annual Financial Statements, has been made available to shareholders in due course.
2. To review and, as the case may be, approve the separate report on the status of consolidated non- financial information for the fiscal year ended December 31, 2020. This report is referred to in section 7 of article 49 of the Commercial Code, which forms part of the Management Report of the Pharma Mar Group.
   To approve the separate report on the status of consolidated non-financial information for the fiscal year ended December 31, 2020. This report is referred to in section 7 of article 49 of the Commercial Code, which forms part of the Management Report of the Pharma Mar Group.

The status of the non-financial information contained in the aforementioned report has been verified by PRICEWATERHOUSECOOPERS Auditores, S.L., and has been made available to shareholders in due course.

1.3. To review and, as the case may be, approve the proposed application of the Company's results for the year ended December 31, 2020.

To approve the proposal for the application of the result for the year ended December 31, 2020 prepared by the Board of Directors at a meeting held on February 26, 2021 and, consequently, distribute the profit for the year 2020, which amounts to TWENTY EIGHT MILLION NINE HUNDRED FIFTY-TWO THOUSAND NINETY EUROS AND FIFTY-TWO CENTS (€ 28,952,090.52), in the following terms:

1. To dividends to be distributed among the shares of the Company with the right to receive it at any time: € 11,012,944.20. This is equivalent to distributing a fixed dividend of 0.60 euros gross per share for all of the 18,354,907 shares into which the Company's share capital is divided on the date of preparation of the annual accounts.
2. To compensate the negative results account from previous years: € 17,939,146.32.

The ordinary dividend proposed by the Board of Directors consists of an amount of 0.60 gross euros for each of the shares of the Company with the right to receive it on the date on which the corresponding payment is made, an amount from which the withholding tax that is applicable.

Consequently, the final amounts destined to the distribution of the dividend and to compensate the negative results account from previous years may not coincide with those referred to in sections (i) and

1. above, and will be determined at the time of the dividend distribution, in depending on the Company's outstanding shares and those held in treasury stock at that time.

The dividend will be paid on April 30, 2021, through Banco Santander, S.A. in accordance with the operating rules of the Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, SAU (IBERCLEAR).

1.4. To review and, as the case may be, approve the corporate management during the fiscal year 2020.

To approve the corporate management by the Board of Directors of Pharma Mar, S.A. for fiscal year 2020.

RESOLUTION TO AGENDA ITEM 2

To reelect the Statutory Auditors of the Company and its Consolidated Group.

Having ended the one-year period for which PRICEWATERHOUSECOOPERS Auditores S.L. was reelected as Auditor of the Company and its Consolidated Group, to reelect as Auditor of the Company and its Consolidated Group for a period of one year to said company, with registered offices in Madrid, Paseo de la Castellana 259-B, and holding Spanish Tax ID (C.I.F.) B-79031290, and registered in the Special Registry of Statutory Auditors under number S0242.

This resolution was proposed by the Audit Committee and subsequently confirmed by the Board of Directors of Pharma Mar, S.A.